ABSTRACT NUMBER: ESOC2026A939 EARLY ADJUVANT TIROFIBAN AFTER ENDOVASCULAR THROMBECTOMY: A REAL-WORLD, PROPENSITY-MATCHED ANALYSIS FROM THE TAIWAN TREAT-AIS REGISTRY

Abstract Background and aims The efficacy and safety of tirofiban administered within 24 hours after endovascular thrombectomy (EVT) remain debated. We evaluated the impact of adjuvant tirofiban on functional outcomes and hemorrhage risks using the Taiwan TREAT-AIS Nationwide Registry. Methods We conducted a retrospective multicenter study (Jan 2019–Feb 2025) of acute ischemic stroke patients receiving EVT. Tirofiban users were matched 1:4 with non-users using propensity scores based on age, gender, initial NIHSS, baseline blood pressure, and large-artery atherosclerosis. Primary outcomes were 90-day functional independence (modified Rankin Scale, mRS 0-2) and ordinal mRS shift. Safety outcomes included symptomatic intracranial hemorrhage (sICH), any radiological ICH, and mortality. Analyses employed multivariable logistic and partial proportional-odds models adjusting for confounders. Results Of 3,021 eligible patients, 245 received tirofiban. After matching, 245 users were compared with 980 non-users. Baseline characteristics were well-balanced. Tirofiban use was associated with significantly higher 90-day functional independence (adjusted OR [aOR] 2.06, 95% CI 1.48–2.87, p<0.001) and a favorable shift in mRS distribution (aOR 0.55, 95% CI 0.42–0.71, p<0.001). Moreover, 90-day mortality was significantly lower in the tirofiban group (aOR 0.49, 95% CI 0.30–0.79, p=0.004). No significant differences were observed for sICH (aOR 0.97, 95% CI 0.49–1.90, p=0.919) or any radiological ICH (aOR 0.77, 95% CI 0.55–1.08, p=0.129). Conclusions In this nationwide registry, tirofiban use within 24 hours post-EVT was associated with improved functional outcomes and reduced mortality without increasing intracranial hemorrhage risks. These findings support the therapeutic benefit and safety of early adjuvant tirofiban in selected patients. Conflict of interest All authors, Kuo-Cheng Chang, Nien-Chen Liao, Po-Lin Chen, nothing to disclose. Table 1 - belongs to Methods Table 2 - belongs to Results

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.483
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A939 EARLY ADJUVANT TIROFIBAN AFTER ENDOVASCULAR THROMBECTOMY: A REAL-WORLD, PROPENSITY-MATCHED ANALYSIS FROM THE TAIWAN TREAT-AIS REGISTRY

Kuo‐Cheng Chang, Nien-Chen Liao, Po-Lin Chen
European Stroke Journal
Acute Ischemic Stroke Management
article

ABSTRACT NUMBER: ESOC2026A939 EARLY ADJUVANT TIROFIBAN AFTER ENDOVASCULAR THROMBECTOMY: A REAL-WORLD, PROPENSITY-MATCHED ANALYSIS FROM THE TAIWAN TREAT-AIS REGISTRY

Kuo‐Cheng Chang, Nien-Chen Liao, Po-Lin Chen
article en

Abstract

Abstract Background and aims The efficacy and safety of tirofiban administered within 24 hours after endovascular thrombectomy (EVT) remain debated. We evaluated the impact of adjuvant tirofiban on functional outcomes and hemorrhage risks using the Taiwan TREAT-AIS Nationwide Registry. Methods We conducted a retrospective multicenter study (Jan 2019–Feb 2025) of acute ischemic stroke patients receiving EVT. Tirofiban users were matched 1:4 with non-users using propensity scores based on age, gender, initial NIHSS, baseline blood pressure, and large-artery atherosclerosis. Primary outcomes were 90-day functional independence (modified Rankin Scale, mRS 0-2) and ordinal mRS shift. Safety outcomes included symptomatic intracranial hemorrhage (sICH), any radiological ICH, and mortality. Analyses employed multivariable logistic and partial proportional-odds models adjusting for confounders. Results Of 3,021 eligible patients, 245 received tirofiban. After matching, 245 users were compared with 980 non-users. Baseline characteristics were well-balanced. Tirofiban use was associated with significantly higher 90-day functional independence (adjusted OR [aOR] 2.06, 95% CI 1.48–2.87, p<0.001) and a favorable shift in mRS distribution (aOR 0.55, 95% CI 0.42–0.71, p<0.001). Moreover, 90-day mortality was significantly lower in the tirofiban group (aOR 0.49, 95% CI 0.30–0.79, p=0.004). No significant differences were observed for sICH (aOR 0.97, 95% CI 0.49–1.90, p=0.919) or any radiological ICH (aOR 0.77, 95% CI 0.55–1.08, p=0.129). Conclusions In this nationwide registry, tirofiban use within 24 hours post-EVT was associated with improved functional outcomes and reduced mortality without increasing intracranial hemorrhage risks. These findings support the therapeutic benefit and safety of early adjuvant tirofiban in selected patients. Conflict of interest All authors, Kuo-Cheng Chang, Nien-Chen Liao, Po-Lin Chen, nothing to disclose. Table 1 - belongs to Methods Table 2 - belongs to Results

European Stroke JournalVol. 11(Supplement_1)
Taichung Veterans General Hospital (TW)
Good health and well-being
Openalex Percentile: Top 8%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.